USPTO serial 85960315
RHEUMASTRAT
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- KENEALY, NATALIE LANGFORD
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with RHEUMASTRAT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Crumlin, Antrim, GB
Crumlin, Antrim, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alicia Morris Groos
ALICIA MORRIS GROOS Norton Rose Fulbright US LLP98 SAN JACINTO BLVD STE 1100AUSTIN, TX 78701-4255UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry, science, photography, agriculture, horticulture and forestry; chemical reagents other than for medical purpose; enzymes for scientific and research purposes and proteins for industrial use; diagnostic preparations for scientific purposes; clinical diagnostic preparations or reagents other than for medical use; diagnostic preparations, namely, diagnostic scanning agents; diagnostic testing materials, namely, diagnostic preparations, reagents and contrast media other than for medical use; chemical reagents for use in diagnostic tests, other than for medical use; clinical diagnostic reagents for laboratory in vitro and/or vivo use | ACTIVE | — |
| 005 | Pharmaceutical preparations for the treatment of rheumatoid arthritis, and pharmaceutical substances, namely, for the prediction of response to anti-Tumor Necrosis Factor, also known as TNF, therapies and sanitary preparations for the prediction of response to anti-Tumor Necrosis Factor therapies; diagnostic preparations and substances for medical use; diagnostic kits consisting primarily of multiplex polymerase chain reaction reagents and biochip array reagents; clinical diagnostic preparations for medical use; clinical diagnostic reagents for medical in vitro and/or vivo use; diagnostic scanning agents for in-vivo use used for the prediction of response to anti-Tumor Necrosis Factor therapies; diagnostic testing materials, namely, diagnostic preparations, reagents and contrast media for medical use; clinical medical reagents; reagents for use in diagnostic tests for medical purposes; reagents for use with analyzers for medical purposes; parts and fittings for all the aforesaid goods, namely, multiplex polymerase chain reaction reagents and biochip array reagents; chemical reagents for medical purposes; enzymes for medical purposes | ACTIVE | — |
| 042 | Scientific and technological services, namely, research and design in the field of rheumatoid arthritis; medical research services; clinical research services, namely, conducting clinical trials for others; biological research; conducting clinical trials for others, namely, analysis, management and reporting of clinical data; consulting services in the field of quality assessment services for clinical laboratories; chemical research; chemical laboratory services; chemical analysis; scientific and medical laboratory services for analytical testing; medical laboratory services; biochemistry research and consultant advisory services; conducting clinical trials for others; providing computer aided diagnostic testing services for predicting response to anti-Tumor Necrosis Factor therapies for others in the field of science and research related thereto; scientific and technological services, namely, development of test equipment for medical apparatus for others; advice, information and consultancy services relating to all the aforesaid services | ACTIVE | — |
| 044 | Medical services; providing health advice and information services; medical care services; health clinic services; healthcare services, namely, geriatric health care, physical therapy; medical health assessment services, namely, providing prediction of response to anti-Tumor Necrosis Factor therapies; diagnostic health screening services in the field of rheumatoid arthritis ; medical testing for prediction of response to therapy; medical diagnostic testing services; genetic testing for medical for medical purposes; medical clinics; advice, information and consultancy services for all of the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Randox Laboratories Ltd
- Other trademarks owned by Randox Laboratories Ltd
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named RHEUMASTRAT
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 6, 2016 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 5, 2016 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 16, 2016 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 13, 2016 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jan 27, 2016 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jan 27, 2016 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 27, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 30, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 29, 2015 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jul 22, 2015 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jul 22, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 17, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 16, 2015 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 12, 2015 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 27, 2015 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 27, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 5, 2014 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 10, 2014 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 10, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 21, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 7, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 7, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 6, 2014 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 6, 2014 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 6, 2014 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 6, 2014 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 1, 2014 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 1, 2014 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 1, 2014 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 8, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 8, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 4, 2014 | ALIE | ASSIGNED TO LIE | — |
| Mar 25, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 26, 2013 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 26, 2013 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 26, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 24, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 24, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 18, 2013 | NWAP | NEW APPLICATION ENTERED | — |